Back
Amicus Therapeutics Quote, Financials, Valuation and Earnings
U.S. Government Report Alert Tuesday
Discover the Secret Loophole
Buy
57
FOLD
Amicus Therapeutics
Last Price:
11.34
Seasonality Move:
7.73%
7 Day Trial
ALL ACCESS PASS
$
7
Write This Down: Tuesday at 2 p.m. ET!
Don't Miss Our LIVE TradeAmicus Therapeutics Price Quote
$11.34
-0.13 (-1.13%)
(Updated: November 4, 2024 at 5:55 PM ET)
Amicus Therapeutics Key Stats
Buy
57
Amicus Therapeutics (FOLD)
is a Buy
Day range:
$11.28 - $11.69
52-week range:
$9.02 - $14.57
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
7.57
P/B ratio:
25.67%
Volume:
2.3M
Avg. volume:
2.4M
1-year change:
4.46%
Market cap:
$3.4B
Revenue:
$399.4M
EPS:
$-0.39
How Much Does Amicus Therapeutics Make?
-
How Much Are Amicus Therapeutics's Sales Annually?
FOLD Revenues are $399.4M -
How Much Profit Does Amicus Therapeutics's Make A Year?
FOLD net income is -$151.6M
Is Amicus Therapeutics Growing As A Company?
-
What Is Amicus Therapeutics's Growth Rate Quarterly?
Quarterly YoY revenue growth is 0.34% -
What Is Amicus Therapeutics's EPS Quarterly YoY Growth Rate?
Quarterly, year-over-year diluted EPS growth rate is 0%
Amicus Therapeutics Stock Price Performance
-
Did Amicus Therapeutics Stock Go Up Last Month?
Amicus Therapeutics share price went up by 7.6% last month -
Did FOLD's Share Price Rise Over The Last Year?
FOLD share price rose by 4.46% over the past 1 year
What Is Amicus Therapeutics 52-Week High & Low?
-
What Is Amicus Therapeutics’s 52-Week High Share Price?
Amicus Therapeutics has traded as high as $14.57 over the past 52 weeks -
What Is Amicus Therapeutics’s 52-Week Low Share Price?
Amicus Therapeutics has traded as low as $9.02 over the past 52 weeks
Amicus Therapeutics Price To Free Cash Flow
Data Unavailable
Is It Risky To Buy Amicus Therapeutics?
-
How Much Debt Does Amicus Therapeutics Have?
Total long term debt quarterly is $388.9M -
How Much Cash Does Amicus Therapeutics Have?
Cash and short term investments quarterly total is $260.1M -
What Is Amicus Therapeutics’s Book Value Per Share?
Book value per share is 0.45
Is Amicus Therapeutics Cash Flow Positive?
-
What Is FOLD Cash Flow From Operations?
Cash flow from operations (TTM) is -$41.9M -
What Is Amicus Therapeutics’s Cash Flow From Financing?
Cash flow from financing (TTM) is $31.7M -
What Is Amicus Therapeutics’s Cash Flow From Investing?
Cash flow from investing (TTM) is -$2.6M
Amicus Therapeutics Return On Invested Capital
-
Is Management Doing A Good Job?
FOLD return on invested capital is -22.81% -
What Is Amicus Therapeutics Return On Assets?
ROA measures how assets are converting to revenues and is -15.97% -
What Is FOLD Return On Equity?
ROE is a measure of profitability and is -89.45%
Amicus Therapeutics Earnings Date & Stock Price
-
What Is Amicus Therapeutics's Stock Price Today?
A single share of FOLD can be purchased today for 11.47 -
What Is Amicus Therapeutics’s Stock Symbol?
Amicus Therapeutics trades on the nasdaq under the ticker symbol: FOLD -
When Is Amicus Therapeutics’s Next Earnings Date?
The next quarterly earnings date for Amicus Therapeutics is scheduled on November 6, 2024 -
When Is FOLD's next ex-dividend date?
Amicus Therapeutics's next ex-dividend date is May 1, 2020 -
How To Buy Amicus Therapeutics Stock?
You can buy Amicus Therapeutics shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.
Amicus Therapeutics Competitors
-
Who Are Amicus Therapeutics's Competitors?
Below is a list of companies who compete with Amicus Therapeutics or are related in some way:
Amicus Therapeutics Dividend Yield
-
What Is FOLD Dividend Yield?
Amicus Therapeutics’s dividend yield currently is 0% -
What Is Amicus Therapeutics’s Payout Ratio?
Amicus Therapeutics’s payout ratio is 0% -
When Did Amicus Therapeutics Last Pay A Dividend?
The latest dividend pay date is November 5, 2024 -
What Is Amicus Therapeutics’s Dividend Per Share?
Amicus Therapeutics pays a dividend of $0.00 per share
Amicus Therapeutics Analyst Estimates
| YoY Growth | Past Surprise | |
|---|---|---|
| EPS: | 0% | 283.63% |
| Revenue: | 34.04% | 4.47% |
Analyst Recommendations
| Buy Recommendations: | 9 |
|---|---|
| Hold Recommendations: | 2 |
| Sell Recommendations: | 0 |
| Price Target: | 17.33 |
| Upside from Last Price: | 51.12% |